Patent · US Active

6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection

US12351575B2 · kind B2 · utility

0Cited by

5References

13Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Lei Guo · Kowloon, CN
Taishan Hu · Shanghai, CN
Buyu Kou · Shanghai, CN
Xianfeng Lin · Shanghai, CN
Hong Shen · Shanghai, CN
Houguang Shi · Shanghai, CN
Shixiang Yan · Shanghai, CN
Weixing Zhang · Shanghai, CN
Zhisen Zhang · Shanghai, CN
Mingwei Zhou · Shanghai, CN
Wei Zhu · Shanghai, CN

Key dates

Filing date	Aug 5, 2019
Grant date	Jul 8, 2025
Priority date	—
Expiry date	Aug 27, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/519
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W and n are as described herein, compositions including the compounds and methods of using the compounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.